Melatonin suppression by melanopsin-weighted light in patients with bipolar I disorder compared to healthy controls by Ritter, Philipp et al.
 J Psychiatry Neurosci 1
© 2019 Joule Inc. or its licensors
Research Paper
Melatonin suppression by melanopsin-weighted  
light in patients with bipolar I disorder compared  
to healthy controls
Philipp Ritter, MD; Falk Wieland, PhD; Debra J. Skene, PhD; Andrea Pfennig, MD;  
Maria Weiss, MD; Michael Bauer, MD; Emanuel Severus, MD; Henry Güldner, PhD;  
Cathrin Sauer, DiplBiomath; Bettina Soltmann, MSc; Stefanie Neumann, MD
Introduction
Bipolar disorder is a severe mental disorder that has a signifi-
cant negative impact on psychosocial functioning and quality 
of life; it is associated with high rates of suicide.
There is currently no comprehensive neurobiological 
model that explains the mechanisms causing, modulating 
and sustaining bipolar disorder. More recently, however, evi-
dence has accumulated that its onset and course are influ-
enced by alterations in environmental light conditions and 
aberrant melatonin signalling.1 An initial study demonstrat-
ing an inverse correlation between the springtime change in 
light intensity (solar insolation) and age at onset of the disor-
der2 has been replicated in 2 follow-up studies.3,4 Peaks for 
both manic and depressive episodes appear to follow a sea-
sonal pattern.5 Melatonin levels have been found to be re-
duced in bipolar disorder,6 and exposure to sunlight has been 
found to shorten time to remission in bipolar depression.7 
Further studies have also demonstrated that restricting light 
exposure has a therapeutic antimanic effect.8,9
The synthesis of melatonin is suppressed by light, particu-
larly in the short-wavelength blue range,10,11 and transmitted 
via neural pathways involving the suprachiasmatic nuclei 
and the autonomic nervous system innervating the pineal 
gland. Melatonin plays a central role in modulating sleep 
timing and synchronizing circadian rhythms, both processes 
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Background: Multiple lines of evidence suggest that the onset and course of bipolar disorder is influenced by environmental light condi­
tions. Increased suppression of melatonin by light (supersensitivity) in patients with bipolar disorder has been postulated as an endo­
phenotype by several studies. However, due to methodological shortcomings, the results of these studies remain inconclusive. This 
study investigated melatonin suppression in euthymic patients with bipolar I disorder using evening blue light specifically targeting the 
melanopsin system. Methods: Melatonin suppression was assessed in euthymic patients with bipolar I disorder and healthy controls by 
exposure to monochromatic blue light (λmax = 475 nm; photon density = 1.6 × 1013 photons/cm2/s) for 30 minutes at 2300 h, administered 
via a ganzfeld dome for highly uniform light exposure. Serum melatonin concentrations were determined from serial blood sampling via 
radioimmunoassay. All participants received mydriatic eye drops and were genotyped for the PER3 VNTR polymorphism to avoid or 
 adjust for potential confounding. As secondary outcomes, serum melatonin concentrations during dark conditions and after monochro­
matic red light exposure (λmax = 624 nm; photon density = 1.6 × 1013 photons/cm2/s) were also investigated. Changes in subjective alert­
ness were investigated for all 3 lighting conditions. Results: A total of 90 participants (57 controls, 33 bipolar I disorder) completed the 
study. Melatonin suppression by monochromatic blue light did not differ between groups (F1,80 = 0.56; p = 0.46). Moreover, there were no 
differences in melatonin suppression by monochromatic red light (F1,82 = 1.80; p = 0.18) or differences in melatonin concentrations during 
dark conditions (F1,74 = 1.16; p = 0.29). Healthy controls displayed a stronger increase in subjective alertness during exposure to blue 
light than patients with bipolar I disorder (t85 = 2.28; p = 0.027). Limitations: Large interindividual differences in melatonin kinetics may 
have masked a true difference. Conclusion: Despite using a large cohort and highly controlled laboratory conditions, we found no differ­
ences in melatonin suppression between euthymic patients with bipolar I disorder and healthy controls. These findings do not support 
the  notion that supersensitivity is a valid endophenotype in bipolar I disorder.
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known to be altered in patients with bipolar disorder.12,13 Re-
search in the area of nonvisual light responses has received 
substantial stimulus from the discovery of the novel photo-
pigment melanopsin and description of intrinsically photo-
sensitive retinal ganglion cells (ipRGCs).14 Melanopsin-
containing ipRGCs appear to be the main source and 
gateway for nonvisual information on general levels of 
 environmental light transmitted to the central nervous sys-
tem. The absorption maximum for melanopsin is estimated 
to be in the blue spectrum, with a peak at ~480 nm.15,16 Aside 
from its critical role in circadian entrainment and melatonin 
suppression, ipRGC signalling has been shown to be in-
volved in the pupillary light reflex, arousal and vision itself.17
Nonvisual light responses appear to be modulated by a 
variable number tandem repeat (VNTR) polymorphism on 
the PER3 gene; the 5/5 (PER35/5) genotype displays a more 
sensitive response to blue-enriched light with respect to 
 melatonin suppression compared to the PER34/4 genotype.18 
Interestingly PER35/5 has also been shown to be associated 
with an earlier disease onset in patients with bipolar disor-
der, further underscoring a possible modulating effect of 
nonvisual light processing in modifying disease course.19
Several studies have investigated non-image-forming func-
tions in patients with bipolar disorder by measuring melatonin 
suppression by bright white light in the evening or at night, 
but results have been inconsistent. Some studies6,20–23 but not 
all24,25 found increased melatonin suppression in patients with 
bipolar disorder, leading to the proposition that supersensitiv-
ity to light may be an endophenotype21 in bipolar I disorder. 
This view has been enforced by the observation that the mood-
stabilizing drugs lithium and valproate both reduce melatonin 
sensitivity to light.26,27 However, these studies had a variety of 
methodical drawbacks: most had small samples of patients 
with bipolar disorder (n < 20), included patients in manic or 
depressive episodes, and used white light with an undefined 
spectral composition. Therefore, it remains uncertain whether 
the increased light sensitivity occurs in the melanopsin (blue) 
spectrum or in other components of white light (e.g., red). In 
addition, none of the studies dilated the participants’ pupils or 
used ganzfeld domes, making it impossible to estimate accu-
rately the photon density of the light stimulus and increasing 
the risk of bias due to medication or illness effects on patients’ 
pupil size.28 Moreover, none of the studies have specifically in-
vestigated melatonin suppression taking into account the spec-
tral sensitivity of melanopsin and the potentially confounding 
effect of unequal distribution of the PER3 VNTR genotype.
The primary aim of the present study was to determine 
whether patients with bipolar I disorder were more sensitive 
to melatonin suppression by monochromatic blue light (λmax = 
475 nm) specifically stimulating the melanopsin pathway 
compared with healthy controls.
Our secondary aims were as follows: to determine whether 
patients with bipolar I disorder were more sensitive to melato-
nin suppression by narrow-bandwidth red light (λmax = 624 nm) 
compared with healthy controls, to determine whether patients 
with bipolar I disorder had lower serum melatonin concentra-
tions than healthy controls, and to determine whether patients 
with bipolar I disorder were more sensitive to the subjective 
alerting effects of monochromatic blue light (λmax = 475 nm) as 
measured by the Karolinska Sleepiness Scale (KSS).29 
We also performed exploratory analyses to determine 
whether the PER3 VNTR genotype was associated with 
 melatonin suppression by monochromatic blue light.
Method
Participants
The study was approved by the institutional review board of the 
Medical Faculty of the Technische Universität Dresden 
(IRB00001473 and IORG0001076). We recruited patients with 
 bipolar I disorder from the outpatient departments of 4 hospitals, 
and by advertisement in local newspapers and the websites of 
bipolar advocacy groups. We recruited healthy controls via 
 notice boards and advertisements in local newspapers. After 
providing full informed consent, all participants were assessed 
using the German version of the SCID I interview30 for DSM-IV 
by an experienced psychiatrist. Mood was assessed using the 
Young Mania Rating Scale (YMRS)31 and the Inventory of 
 Depressive Symptoms (IDS).32 Ophthalmological conditions 
were excluded by slit lamp examination, tonometry, and Snellen 
and Ishihara charts. We also recorded body mass index, smoking 
status, current medication, family history of psychiatric disorder 
and past medical history. Further instruments used to character-
ize participants’ sleep and circadian rhythms were the Pittsburgh 
Sleep Quality Index (PSQI),33 the KSS29 and the Morningness–
Eveningness Scale (MEQ).34 We used the Global Assessment of 
Functioning (GAF)35 to quantify overall functioning.
Healthy control participants were excluded if any axis I psy-
chiatric disorder (excluding adjustment disorder in full remis-
sion) or emotionally unstable personality disorder had been 
diag nosed and if first-degree relatives had been diagnosed or 
could be assumed to have an affective, substance use, anxiety 
or psychotic disorder. Patients with bipolar I disorder were ex-
cluded if any additional axis I psychiatric disorder or emotion-
ally unstable personality disorder had been diagnosed. Further 
exclusion criteria for all participants included ophthalmological 
conditions (except for simple myopia/hyperopia); diagnosed 
or probable sleeping disorder; other disorders associated with 
impaired sleep (i.e., polyneuropathy, chronic severe back pain); 
substance use disorder; inflammatory conditions; neurologic 
conditions; cancer; medical conditions deemed incompatible 
with study participation; use of melatonin, pregabalin, gaba-
pentin, benzodiazepines, zopiclone, zolpidem or β-blockers; re-
cent transmeridian travel (past 2 weeks); or shift or night-time 
work (past 3 months). All participants were required to be 
 between 18 and 60 years of age and euthymic at the time of 
 inclusion and on every assessment night (YMRS < 5; IDS < 8). 
The study was conducted during the winter months (Novem-
ber 2015 to March 2016) at latitude 51°N.
Study protocol
Study participants attended the laboratory for assessment on 
a total of 3 occasions. All participants were required to adhere 
to a regular schedule of waking no later than 0730 h, exposing 
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themselves to sunlight in the morning, and switching lights 
off no later than 0000 h on the 4 days leading up to each 
 appointment. These prelaboratory conditions ensured stable 
circadian entrainment and sufficient sleep before the study. 
Adherence was ascertained by diary. On the day of assess-
ment, participants were required to consume no food or caf-
feinated drinks after 1300 h. Participants entered the labora-
tory at 1800 h on the evening of the assessment. After 
clarifying the schedule, evaluating the diary and establishing 
euthymia via YMRS and IDS, we gave participants a standard 
vegetarian meal of 600 calories at 1900 h. Thereafter, an 18G 
intravenous cannula was inserted into a forearm vein and 
7.5 mL of blood was collected into a tube containing EDTA (S-
Monovette K3, Sarstedt) for genetic analyses on the first night.
At 2000 h, all participants were seated in a reclining posi-
tion under dim light conditions (< 10 lux in the direction of 
gaze, incandescent lamps) and allowed to listen to music via 
headphones or read. Participants were instructed to keep their 
eyes open. At 2100 h, lights were turned off and participants’ 
eyes were covered with a standard light-blocking eye mask. 
At 2200 h, participants received mydriatic eye drops (0.5% 
tropicamide and 1.25% phenylephrine)36 bilaterally under dim 
light conditions. Participants were instructed to keep their 
eyes closed between 2100 and 2300 h. During the protocol, 
they were allowed to consume water or herbal tea, but no 
food. Complete pupil dilation was assessed by study person-
nel before light exposure.
Between 2300 and 2330 h, participants were exposed to 1 of 
3 light conditions (dark, red, blue). The sequence of light ex-
posure was randomized, and patients were blinded to light 
condition up to the point of exposure. For a uniform full-field 
exposure of the retina for all participants, we used a half 
sphere (ganzfeld dome, Optopolymer) with an inner diam-
eter of 50 cm. The inner surface was coated with a highly 
 reflective barium sulphate coating. For highly uniform light 
distribution inside the dome, LEDs were mounted inside an 
aperture ring. Standardized light exposure was ensured by a 
chin and forehead rest; participants sat in an upright position. 
Constant retinal illumination was ensured via closed-loop 
constant current LED drivers and integrated continuous pho-
tometric measurement linked to an electronic feedback con-
trol (Appendix 1, Figure S1, available at jpn.ca/190005-a1).
The photon densities of the light stimuli were set to be at the 
midpoint of the sigmoid curve describing melatonin suppres-
sion.11 Light levels were measured with a dummy face at the 
position of the eye (vertical, looking into the sphere; for a de-
tailed description, see Appendix 1, Figure S1). The red expo-
sure condition was set at a wavelength of 624 nm (half band-
width 18 nm) and blue was set at 475 nm (half bandwidth 
25 nm) with equal photon densities of 1.6 × 1013 photons/ 
cm2/s (Table 1). Participants were instructed to keep their eyes 
open throughout the exposure; this was monitored by the 
staff. We calculated photoreceptor-specific illuminance values 
in α-opic lux using the Irradiance Toolbox.37
At 2330 h, participants reclined in their seat and were sub-
jected to renewed darkness until 0000 h.
Blood samples were taken at 2100, 2200, 2300 (before lights 
on), 2330 (with lights on) and at 0000 h (lights off); 5 mL of 
blood was removed and discarded before each sampling. The 
intravenous cannula was kept patent with 10 mL of 0.9% 
NaCl solution.
Patients were asked to rate their subjective sleepiness using 
the KSS at 2100, 2200, 2300, 2315, 2330 and 0000 h.
Laboratory procedures
Blood was collected in 9 mL clotting tubes (S-Monovette Z-Gel, 
Sarstedt) for melatonin analysis and in tubes containing EDTA 
(S-Monovette K3, Sarstedt) for genetic analyses. After centrifu-
gation of the clotting tubes at 1000g for 15 minutes, the super-
natant serum and the EDTA whole blood were stored at −80°C 
until further analysis.
Serum melatonin concentrations were measured in dupli-
cate using a direct radioimmunoassay with 125I-labelled 
 melatonin according to the manufacturer’s protocol (IBL 
 International). Radioactivity was measured in a gamma 
counter LB2111 (Berthold Technologies).
Genomic DNA was extracted from frozen (−80°C) EDTA 
whole blood using a QIAmp DNA blood mini kit (Qiagen) 
according to the manufacturer’s protocol. To quantify and 
 assess the purity of the DNA, the absorbance at 260 nm and 
the ratios A 260/280 and A260/230 were measured using a 
NanoDrop 2000 spectrophotometer (Thermo Fisher).
Polymerase chain reaction (PCR) was performed with the 
following primers: 5’-TGTCTTTTCATGTGCCCTTACTT-3’ 
and 5’-TGTCTGGCATTGGAGTTTGA-3’.38 The PCR reaction 
was carried out in a 25 µL volume containing 150 ng DNA, 0.5 
µM of each primer, 200 µM deoxynucleoside triphosphate, 
1 × Q5 reaction buffer and 0.02 U/µL Q5 high-fidelity DNA 
polymerase (New England Biolabs). After an initial step of 
30 seconds at 98°C, 30 cycles of amplification (10 seconds at 
98°C, 30 seconds at 65°C, 25 seconds at 72°C) and a final elon-
gation step of 5 minutes at 72°C were performed. An aliquot 
of PCR product was analyzed on agarose (2% agarose LE, 
Biozym) gel electrophoresis (5 V/cm for 90 minutes) to dis-
tinguish between the 5 repeat allele (401 bp), the 4 repeat 
 allele (347 bp) and the heterozygotes (347 and 401 bp).
Statistical analysis
We calculated the minimum sample size39 based on previous 
publications6 with mean melatonin suppression (bipolar I dis-
order 62%, healthy controls 40%, standard deviation 15%;  n = 
14 for 1 − β = 0.8, α = 5%).
We compared demographic and clinical characteristics 
 using 2-sided unpaired t tests and χ2 tests as appropriate. In 
Table 1: Photometric properties of the 3 illuminance conditions
Photometric property Dark Red Blue
Peak wavelength, nm — 624 475
Full width at half maximum, nm — 18 25
Number of photons/cm2/s 0 1.6 × 1013 1.6 × 1013
Illuminance, lux 0 9.2 8.0
Irradiance, W/m2 0 5.0 × 10−2 6.6 × 10−2
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cases of significant differences between the bipolar I disorder 
and healthy control groups, we included potential relevant 
confounders in the analysis as covariates.
We made groupwise comparisons following visual inspec-
tion of Q/Q plots and assessment of normal distribution 
 using the Shapiro–Wilk test. We used t tests, Mann–Whitney 
tests, repeated-measures analyses of covariance (ANCOVA) 
and univariate ANCOVA as appropriate to compare differ-
ences in outcomes between the bipolar I disorder and healthy 
control groups.
The primary outcomes were relative and absolute suppres-
sion of serum melatonin concentration 30 minutes after the 
 beginning of exposure to blue light. Relative suppression was 
calculated as ([melatonin at 2300 h − melatonin at 2330 h] / 
melatonin at 2300 h) × 100. We also calculated melatonin sup-
pression by exposure to red light. We evaluated group differ-
ences in relative and absolute suppression using univariate 
ANCOVA with age and chronotype (MEQ score) as covariates.
We evaluated differences in total melatonin concentration 
between patients using repeated-measures ANOVA adjusted 
for age and chronotype.
We evaluated the differential effects of group on changes in 
KSS during exposure to blue light using repeated-measures 
ANCOVA with age and MEQ as covariates. We performed 
post hoc t tests for selected time points.
We calculated differences in distribution of PER3 VNTR 
genotype between the healthy control and bipolar I disorder 
groups using χ2 tests.
We evaluated the relationship between melatonin suppres-
sion and demographic and clinical characteristics using 
 Pearson or Spearman correlation coefficients as appropriate. 
We assessed the effect of mood-stabilizing medication using 
t tests or repeated-measures ANOVA, comparing patients re-
ceiving mood-stabilizers (lithium or valproate; n = 19) to 
those receiving other medications (n = 11).
Results
A total of 116 participants were screened for inclusion in the 
study. Of these, 94 completed at least 1 assessment and 90 
completed all 3 assessments. Only participants completing 
all 3 study nights were included in the analysis. Of the 
healthy controls, 6 declined to participate following screen-
ing, 2 did not respond to further communication, 2 discon-
tinued after 1 study night because of poor tolerability, 2 had 
a positive family history, 1 was consuming cannabis and 1 
was found to be red–green colour-blind. Among bipolar I 
disorder participants, 5 declined following screening, 2 dis-
continued after 1 study night because of poor tolerability, 3 
did not respond to further communication, 2 did not fulfill 
the diagnostic criteria for bipolar I disorder. The partici-
pants in the 2 study groups were well matched for age and 
sex (Table 2).
Melatonin suppression
Narrow-bandwidth blue light led to a measurable relative 
suppression in evening melatonin (11%; standard deviation 
29; Fig. 1). We found no significant differences between 
 patients with bipolar I disorder and healthy controls for 
 either relative (F1,80 = 0.56; p = 0.46) or absolute (F1,80 = 0.0; p = 
0.99) suppression of melatonin by monochromatic blue light 
(Fig. 2; Appendix 1, Figure S4).
We also found no difference between the 2 groups with 
respect to relative (F1,82 = 1.80; p = 0.18) or absolute (F1,82 = 
Table 2: Demographic and clinical characteristics of healthy controls 
and patients with bipolar I disorder
Characteristic
Healthy 
controls  
(n = 57)
Bipolar I 
disorder  
(n = 33) p value*
Age, yr 39.6 ± 9.6 43.3 ± 10.9 0.09
Female, % 63.2 57.6 0.66
PSQI score 3.3 ± 1.9 6.0 ± 4.0 < 0.001
MEQ score 56.8 ± 9.5 51.0 ± 11.8 0.017
GAF score 99.5 ± 1.7 83.0 ± 10.6 < 0.001
Qualified for higher 
education, %
65.5 72.0 0.36†
Positive family history, %‡ 0 24.2
Current medication, %
Lithium — 54.6 —
Valproate — 9.1 —
Lamotrigine — 18.2 —
Olanzapine — 9.1 —
Quetiapine — 18.2 —
Other atypical 
antipsychotic
— 12.1 —
Antidepressant — 15.2 —
GAF = Global Assessment of Functioning; MEQ = Morningness–Eveningness 
Questionnaire; PSQI = Pittsburgh Sleep Quality Index.
Findings are presented as mean ± standard deviation or percent.
*2­tailed t test, unless stated otherwise.
†χ2 test.
‡Parental history of bipolar disorder or schizophrenia.
Fig. 1: Serum melatonin concentration (pg/mL) for all participants 
(n = 90) comparing conditions of no light exposure (dark, black line) 
with exposure to narrow­bandwidth blue light (blue line) between 
2300 and 2330 h. Error bars indicate standard error of the mean.
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0.64; p = 0.43) melatonin suppression by monochromatic red 
light (Fig. 3; Appendix 1, Figure S4).
Participants with bipolar disorder had reduced serum 
 melatonin levels compared with healthy controls during 
dark conditions, but this finding was not statistically signifi-
cant after adjusting for age and chronotype (F1,74 = 1.16; p = 
0.29; Fig. 4).
Participants with bipolar I disorder were more likely to be 
evening types (as assessed by the MEQ) compared with 
healthy controls (t82 = 2.44; p = 0.017; Table 2), but there were 
no significant correlations between MEQ and outcome 
 parameters (Appendix 1, Table S6). Participants with bipolar 
I disorder also described a worse quality of subjective sleep 
(as assessed by PSQI) compared to healthy controls (t88 = 
4.39; p < 0.001)
The use of lithium or valproate did not significantly affect 
melatonin concentrations (F1,31 = 0.44; p = 0.52) or relative (t28 = 
0.81; p = 0.42) or absolute (t28 = 0.04; p = 0.97) melatonin sup-
pression by blue light (Appendix 1, Table S2).
Using Pearson correlations and t tests, we found no signifi-
cant associations between relative melatonin suppression and 
age at onset of disorder (r31 = −0.2; p = 0.2), number of suicide 
attempts (r31 =  −0.06; p = 0.76), positive family history for 
 bipolar I disorder (t28 = 0.72; p = 0.48), GAF (r31 =  −0.1; p = 
0.74) or PSQI (r31 = 0.1; p = 0.59).
Subjective alerting response
Patients with bipolar I disorder had nonsignificantly elevated 
KSS values (F1,79 = 2.04; p = 0.16) during the dark condition, 
indicating higher degrees of sleepiness than healthy controls. 
They also displayed a significantly reduced subjective alert-
ing response (post hoc t85 = 2.28; p = 0.027) during exposure to 
blue light (Fig. 5).
Fig. 2: Box plots of suppression of serum melatonin by narrow­
bandwidth blue light. Positive values denote suppression (2330 h) 
of melatonin relative to baseline (2300 h). 
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Fig. 3: Box plots of suppression of serum melatonin by narrow­
bandwidth red light. Positive values denote suppression (2330 h) of 
melatonin relative to baseline (2300 h). 
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Fig. 4: Serum melatonin concentration (pg/mL) with no light expos­
ure comparing patients with bipolar I disorder and healthy controls. 
Error bars indicate standard error of the mean.
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Fig. 5: Karolinska Sleepiness Scale (KSS) score during narrow­
bandwidth blue light exposure between 2300 and 2330 h comparing 
patients with bipolar I disorder and healthy controls. The bipolar I 
disorder group showed a significantly reduced alerting response to 
the blue light stimulus compared with healthy controls (*p < 0.05). Error 
bars indicate standard error of the mean. Karolinska Sleepiness Scale 
values during blue light exposure, bipolar I disorder versus healthy 
controls.
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PER3 VNTR polymorphism
The observed genotype frequencies of our sample were 43.7% 
(PER34/4), 40.6% (PER34/5) and 15.6% (PER35/5) for patients with 
bipolar I disorder and 41.5% (PER34/4), 49.1% (PER34/5) and 
9.4% (PER35/5) for healthy controls. The PER3 VNTR polymor-
phism was equally distributed between participants with 
 bipolar I disorder and healthy controls (χ22 = 0.95; p = 0.62).
The PER3 VNTR genotype did not correlate with relative 
melatonin suppression (F1,80 = 0.61; p = 0.55) or melatonin con-
centration (F1,75 = 0.07; p = 0.94).
Discussion
Melatonin and melatonin suppression
Contrary to previous publications6,20–23 and a widespread 
 assumption in the literature,1,40 we did not observe a statis-
tically significant increase in light-induced melatonin sup-
pression or reduced levels of serum melatonin in patients 
with bipolar I disorder compared with matched healthy con-
trols. Our study tested the largest sample of participants pub-
lished to date and carefully controlled for factors known to 
confound melatonin assessment. In addition, it was the only 
study that investigated bipolar patients with dilated pupils, 
that restricted investigations to the winter months, and that 
used ganzfeld domes and monochromatic blue light to opti-
mally stimulate the melanopsin–ipRGC pathway. As well, to 
the best of our knowledge this was the only study to take into 
account the effects of a genetic variant that modulates mela-
tonin suppression. Several explanations might account for 
the discrepancy between our study and the previous reports.
First, the previously reported hypersensitivity of patients 
with bipolar disorder to evening light exposure may be at-
tributable to components of the visible spectrum that were 
not explored in our study, including green light components 
at 530 nm, which was only stimulated with 20 α-opic lux 
 under blue light conditions (Appendix 1, Table S8). Because 
other studies did not specify the spectral composition of the 
light sources in detail, we cannot rule out the possibility that 
the studies describing a hypersensitivity primarily exposed 
patients with bipolar I disorder to this wavelength range. 
Based on the now well-established physiology of melatonin 
suppression by light in the blue wavelength range,10,11,18 this 
explanation seems unlikely, but not impossible.
Second, mood-stabilizing medication may have disguised 
a true difference in light-induced melatonin suppression. 
Both lithium and valproate have been found to reduce light-
induced melatonin suppression in healthy volunteers.26,41 Be-
cause a substantial number of our bipolar I disorder partici-
pants were receiving either lithium or valproate, true 
differences may have been masked. Moreover, the study by 
Nurnberger and colleagues6 found an increase in light-
induced melatonin suppression in patients depending on the 
period of medication discontinuation. However, the 2 studies 
showing no abnormal response to light in bipolar I disorder 
were conducted in participants free of psychotropic medica-
tion.24,25 In addition, in our study sample, neither lithium nor 
valproate was found to significantly reduce melatonin sup-
pression. Therefore, mood-stabilizing medication may 
 account for some but not all of the discrepancies.
Third, previous studies have not used mydriatic eye drops 
to assess melatonin suppression. Pupil dilation allows the 
photon density of the light stimulus — the main predictor of 
melatonin suppression — to be estimated accurately. More-
over, group and age differences in average pupil size may 
have contributed to observed differences in the past. In a sep-
arate study, we found patients with bipolar disorder to have 
marginally larger pupils than healthy controls (unpublished 
data) during light exposure. This may have been due to the 
disease itself or an adverse effect of medication. In particular, 
medications with anticholinergic properties are known to 
have mydriatic effects. The previously described supersensi-
tivity of bipolar patients may thus be related to differences in 
pupil diameter.
Fourth, studies suggesting light supersensitivity in bipolar I 
disorder have generally also used longer periods of light 
expos ure (60 to 120 minutes) and started light exposure after 
0000 h. Because light-induced melatonin suppression is 
 affected by the time of light administration,42 this may be a rea-
son for the differences in results; however, no obvious neuro-
endocrine mechanism would plausibly explain these differ-
ences. Duration of light exposure43 also differed between 
studies, and this may have had a relevant effect. Because mela-
tonin is metabolized by hepatic P450 enzymes44 and has a half-
life of approximately 40 minutes, the enzyme-inducing or 
 -inhibiting effects of pharmacotherapy may have masked a true 
effect that would have become apparent after longer exposure.
Finally, elevated melatonin suppression may describe only 
a subgroup of patients with bipolar disorder; study results 
may vary depending on the proportion of this subgroup in 
the sample. However, correlations with clinical parameters 
did not help us identify such a subgroup in our study sample.
Measure of subjective alertness
Contrary to our hypothesis, participants with bipolar disorder 
did not report an increase in subjective alertness during expos-
ure to blue light. In contrast, during the midpoint of blue light 
administration, patients with bipolar I disorder reported a sig-
nificant reduction in subjective alertness as measured by the 
KSS compared with healthy controls. Recent findings related to 
the beneficial therapeutic effects of blue light deprivation dur-
ing episodes of mania8,9 could suggest a hyperactive alerting 
 response to blue light in patients with bipolar disorder. Because 
the KSS has not been used previously in patients with bipolar 
disorder, and subjective ratings of alertness have a high degree 
of random variability, these results should be treated with cau-
tion until they are replicated in an independent sample.
PER3 VNTR
Participants (healthy controls and bipolar I disorder) with a 
PER3 VNTR 5/5 genotype did not exhibit an increase in light-
induced melatonin suppression (Appendix 1, Figure S3, Table 
S7) in contrast to an earlier study of healthy participants.18
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Limitations
Although this was the largest study of melatonin light sensitivity 
(n = 90) in people with bipolar I disorder to date, we observed 
large interindividual differences in melatonin kinetics. Partici-
pants were required to adhere to a regular light/dark and sleep/
wake schedule before the study nights, but adherence was not 
verified by objective measures such as actigraphy. Not all par-
ticipants exhibited a clear evening surge in melatonin, and this 
may have been attributable in part to a phase-delayed lifestyle. 
Differences between groups in light exposure in the days pre-
ceding the study could also have had a direct influence on mela-
tonin suppression, which has been shown to be sensitive to light 
history.44 Future studies could reduce variance by expanding the 
sampling protocol over several days in controlled lighting condi-
tions. Nonetheless, in a population of largely employed partici-
pants, the feasibility for this would be challenging.
Conclusion
There is widespread evidence that the onset and course of bipo-
lar disorder is determined to a certain degree by environmental 
light conditions. Our findings in euthymic bipolar patients sug-
gest that the mediating mechanism is unlikely to be related to an 
increased suppression of melatonin by melanopsin-weighted 
light. In view of the growing knowledge regarding nonvisual 
neuroanatomical pathways in the central nervous system17,45 
that project to areas other than the suprachiasmatic nuclei and 
have been shown to alter brain states on a different time scale,46 
other avenues of research using electrophysiological or func-
tional MRI measures to assess the effect of light on alertness or 
emotion processing should be pursued in this patient group.
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